Yeji

$BEAM

Beam Therapeutics Inc.

Runway:28 mo
NasdaqMarket cap: —CIK 0001745999

Upcoming catalysts

2 surfaced
NDA/BLA filedDate TBD
$BEAMBeam Therapeutics Inc.
risto-cel
“a potential additional $100 million draw upon the acceptance by the U.S. Food and Drug Administration ("FDA") of the Company's biologics license application ("BLA") submission for risto-cel prior to a certain date”
FDA approvalDate TBD
$BEAMBeam Therapeutics Inc.
risto-cel
“a potential additional $100 million draw at the Company's option upon the FDA's approval of the risto-cel BLA prior to a certain date”

Drug pipeline

Long-Term Follow-up Study of patients who received BEAM-101
Hemoglobinopathy
BEAM-302
Alpha 1-Antitrypsin Deficiency
BEAM-201
Lymphoblastic Lymphoma
BEAM-103
Healthy Subjects
BEAM-101
Sickle Cell Disease
BEAM-301: Single dose of BEAM-301 administered by IV
Glycogen Storage Disease Type Ia
risto-cel

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT07373639Long-Term Follow-up Study of patients who received BEAM-101—Recruiting2043-02-12
NCT06389877BEAM-302Phase 2Recruiting2028-05-01
NCT05456880BEAM-101Phase 2Active Not Recruiting2028-02-01
NCT06735755BEAM-301: Single dose of BEAM-301 administered by IVPhase 2Recruiting2027-12-30
NCT05885464BEAM-201Phase 2Active Not Recruiting2026-12-01
NCT07304791BEAM-103Phase 1Recruiting2026-01-29